A Mitochondria-Targeted Iridium(III) Complex as a Potent Type-I/II Photosensitizer for Pyroptosis-Based Breast Cancer Therapy
Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 18450-18469
DOI: 10.1021/acs.jmedchem.6c00856 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 23.07.2026. Verfasst von Chunjie Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine a…. Hauptthemen laut MEDLINE: Pyroptosis, Iridium, Photosensitizing Agents, Mitochondria. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Wenzhou Medical University, Ningbo Top Medical and Health Research Program, Ningbo Clinical Research Center for Orthopedics, Sports Medicine and Rehabilitation.
Abstract (Originalsprache)
Type-I photodynamic therapy (PDT) is a promising strategy for treating hypoxic tumors because it overcomes the oxygen dependence of traditional PDT. However, the rational design of a potent Type-I photosensitizer that simultaneously achieves subcellular organelle targeting and activates the pyroptotic cell-death pathway remains a formidable challenge. Herein, we report the development of a “Swiss-army-knife” iridium(III) complex, termed Mito-Ir, that concurrently integrates mitochondria targeting, phosphorescence imaging, Type-I/II reactive oxygen species generation, photocatalytic oxidation of 1,4-dihydronicotinamide adenine dinucleotide (NADH) and pyroptosis induction, offering a “one-for-all” platform for high-performance breast-cancer PDT. Upon light irradiation, Mito-Ir triggers severe mitochondrial dysfunction, activating the caspase-3/GSDME pathway to induce pronounced pyroptosis. This pathway not only overcomes apoptosis resistance but also elicits immunogenic cell death through the release of cytokines and damage-associated molecular patterns, thereby activating antitumor immunity. Both in vitro and in vivo studies confirmed its potent antitumor efficacy, underscoring its potential as a pioneering pyroptosis-based therapeutic strategy for breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life sciences, Cixi Biomedical Research Institute, Wenzhou Medical…
- Department of Pharmacy, Ningbo No.6 Hospital, Ningbo315000, P. R.China.
- Department of Hand Microsurgery and Plastic Reconstructive Surgery, Ningbo No.6 Hospital, Ningbo315000, P. R. China.
ORCID-Profile: Jiaxi Ru
Förderung
- Wenzhou Medical University
- Ningbo Top Medical and Health Research Program
- Ningbo Clinical Research Center for Orthopedics, Sports Medicine and Rehabilitation
- Ningbo Health Technology Project
- Yinzhou District Livelihood Science and Technology Project
- Public Welfare Science and Technology Projects of Cixi
Zitieren
APA
Wei, C., Xu, K., Peng, J., Quan, X., Zhao, S., Mou, Y., Xu, K., Ru, J., Shao, C., & Shen, Z. (2026). A Mitochondria-Targeted Iridium(III) Complex as a Potent Type-I/II Photosensitizer for Pyroptosis-Based Breast Cancer Therapy. Journal of Medicinal Chemistry, 69(15), 18450-18469. https://doi.org/10.1021/acs.jmedchem.6c00856
Vancouver
Wei C, Xu K, Peng J, Quan X, Zhao S, Mou Y, et al. A Mitochondria-Targeted Iridium(III) Complex as a Potent Type-I/II Photosensitizer for Pyroptosis-Based Breast Cancer Therapy. Journal of Medicinal Chemistry. 2026;69(15):18450-18469. doi:10.1021/acs.jmedchem.6c00856
BibTeX
@article{Wei2026,
author = {Wei, Chunjie and Xu, Kuang and Peng, Jie and Quan, Xiaoting and Zhao, Shuhan and Mou, Yongxiao and Xu, Ke and Ru, Jiaxi and Shao, Can and Shen, Zhifa},
title = {A Mitochondria-Targeted Iridium(III) Complex as a Potent Type-I/II Photosensitizer for Pyroptosis-Based Breast Cancer Therapy},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {15},
pages = {18450--18469},
doi = {10.1021/acs.jmedchem.6c00856}
}
EUVIMED